Vanda Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vanda Pharmaceuticals, Inc.
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.
Court of Federal Claims lets Vanda’s suit against the agency go forward but notes a ruling for the company could undermine FDA’s ability to provide assistance to other brand name and generic manufacturers.
- Specialty Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.